The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Oragenics Inc. (OGEN) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -4.41%, to $0.13. The Oragenics Inc. has recorded 156,334 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split.
Oragenics Inc. is listed on the AMEX as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $0.14 and fluctuated between $0.1384 as its day high and $0.1250 as its day low. The current market capitalization of Oragenics Inc. is $16.71M. A total of 1.54 million shares were traded on the day, compared to an average of 678.49K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, OGEN has seen 0 BUY and 4 SELL insider trades, representing the acquisition of 0 and the disposition of 266,334 shares. Over the last 12 months, there were 9 BUYs and 4 SELLs from insiders. Insiders purchased 433,922 shares during that period but sold 266,334.
In the most recent transaction, KOSKI ROBERT C sold 42,357 shares of OGEN for 0.11 per share on Dec 30. After the transaction, the Director now owns 1,102,295 company shares. In a previous transaction on Dec 29, KOSKI ROBERT C sold 36,648 shares at 0.11 per share. OGEN shares that Director owns now total 176,191.
Among the insiders who sold shares, KOSKI ROBERT C disposed of 140,497 shares on Dec 15 at a per-share price of $0.18. This resulted in the Director holding 1,144,652 shares of OGEN after the transaction. In another insider transaction, KOSKI ROBERT C sold 25,000 shares at $0.17 per share on Dec 14. Company shares held by the Director now total 1,285,149.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for OGEN in the last 3 months, the mean price target is $1.50 with high estimates of $1.50 and low estimates of $1.50. In terms of 52-week highs and lows, OGEN has a high of $0.56 and a low of $0.10.
As of this writing, OGEN has an earnings estimate of -$0.05 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$0.05. The company reported an EPS of -$0.05 in the last quarter, which was -150.00% lower than expectations of -$0.02.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OGEN is Buy with a score of 0.00. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.